Salix Pharmaceuticals v. Saba Ilac: Rifaximin Patent Settlement Unpacked

Case Overview

In a significant development for pharmaceutical patent litigation, Salix Pharmaceuticals, Inc. and its co-plaintiffs reached a confidential settlement with Turkish generic manufacturer Saba Ilac Sanayi Ve Ticaret A.S., resolving a high-stakes Hatch-Waxman patent infringement dispute over generic rifaximin 550 mg tablets — the active ingredient in blockbuster gastrointestinal drug Xifaxan®. Filed April 4, 2025, in the District of New Jersey and closed September 15, 2025, the case concluded in just 164 days under Case No. 1:25-cv-02307.

The swift resolution, achieved through a Confidential Settlement and License Agreement, avoided costly full-scale patent litigation across twelve asserted patents. Critically, the settlement preserved Saba Ilac’s Paragraph IV certification rights while terminating the 30-month FDA approval stay — a nuanced outcome with notable implications for ANDA litigation strategy, pharmaceutical IP portfolio management, and generic market entry timing.

For patent attorneys, in-house IP counsel, and R&D teams operating in the pharmaceutical space, this case offers instructive lessons on litigation economics, settlement leverage, and the strategic value of Hatch-Waxman procedural mechanisms.

The Parties

Patents at Issue

Plaintiffs asserted twelve U.S. patents, forming a dense defensive portfolio protecting Xifaxan® across composition, formulation, and method-of-treatment claims:

• • U.S. Patent No. 7,928,115 — rifaximin polymorphic forms
• • U.S. Patent No. 8,193,196 — pharmaceutical compositions of rifaximin
• • U.S. Patent No. 8,309,569, 8,642,573, 8,829,017, 8,946,252, 8,969,398 — additional rifaximin formulation and treatment patents
• • U.S. Patent Nos. 10,456,384, 10,765,667, 11,564,912, 11,779,571 — later-generation patents covering treatment methods and extended IP coverage

The Accused Product

Saba Ilac’s ANDA product — generic rifaximin 550 mg tablets — directly targeted Xifaxan®’s market position. Under Hatch-Waxman, Saba’s Paragraph IV certification alleged that the asserted patents were invalid, unenforceable, or would not be infringed by its generic product.

Legal Representation

Plaintiff Counsel: Harvey Bartle IV of Morgan, Lewis & Bockius LLP — a premier Am Law 50 firm with deep pharmaceutical patent litigation expertise

Defendant Counsel: Eric I. Abraham and Kristine L. Butler of Hill Wallack LLP — New Jersey-based firm recognized for ANDA and Hatch-Waxman defense work

Litigation Timeline & Procedural History

The 164-day resolution is notably swift for multi-patent pharmaceutical litigation, suggesting early settlement negotiations ran parallel to initial pleadings — a pattern increasingly common in Hatch-Waxman disputes where litigation costs quickly escalate across large patent portfolios. No claim construction hearing, summary judgment motions, or trial proceedings appear to have reached conclusion before settlement was achieved, reflecting a purely pre-trial resolution.

The Verdict & Legal Analysis

Outcome

The case was dismissed without prejudice and without costs, disbursements, or attorney fees pursuant to a Confidential Settlement and License Agreement. No damages were awarded, and no injunctive relief was issued. The court retained jurisdiction to enforce the settlement stipulation and related agreements.

Two procedurally significant outcomes were embedded within the settlement:

• • Paragraph IV Certifications Preserved: Plaintiffs acknowledged that Saba Ilac is entitled to maintain its Paragraph IV certifications to all twelve asserted patents under 21 C.F.R. § 314.94(a)(12)(v).
• • 30-Month Stay Terminated: The parties agreed to terminate the 30-month FDA approval stay applicable to Saba’s ANDA under 21 U.S.C. § 355(j)(5)(B)(iii).

Verdict Cause Analysis

This was an infringement action initiated under the Hatch-Waxman Act. Salix’s filing of the infringement suit within 45 days of receiving Saba Ilac’s Paragraph IV certification notice automatically triggered the 30-month stay, blocking FDA final approval of the generic ANDA during that period. By agreeing to terminate this stay as part of the settlement, Salix effectively allowed Saba Ilac’s ANDA to proceed toward FDA approval — indicating the settlement likely includes a negotiated future market entry date for the generic product.

The confidential nature of the settlement agreement prevents public analysis of specific license terms, royalty structures, or agreed market entry dates. However, the combination of stay termination and preserved Paragraph IV certifications strongly suggests Salix granted Saba Ilac a license with a defined entry date — the standard commercial outcome in settled Hatch-Waxman disputes.

Legal Significance

The preservation of Saba Ilac’s Paragraph IV certification rights is a legally significant concession. Paragraph IV certifications, once established, carry independent regulatory value and inform the FDA’s Orange Book exclusivity framework. Salix’s acknowledgment that these certifications may be maintained — rather than withdrawn as a settlement condition — may reflect the strength of Saba Ilac’s invalidity or non-infringement positions developed during early litigation.

The “dismissed without prejudice” designation, while standard in ANDA settlements, means claims could theoretically be reasserted if license agreement terms are breached — a common enforcement mechanism in pharmaceutical IP settlements.

Strategic Takeaways

For Patent Holders: Salix’s twelve-patent assertion strategy exemplifies portfolio depth as settlement leverage. Broad patent thickets increase litigation cost and complexity for generic challengers, accelerating settlement even where individual patent validity may be uncertain.

For Accused Infringers/Generic Manufacturers: Saba Ilac’s outcome — a license plus stay termination — represents a commercially favorable resolution. Retaining Paragraph IV certifications preserves future regulatory positioning and potential 180-day exclusivity considerations for first filers in related proceedings.

For R&D Teams: Companies developing products in markets protected by dense patent portfolios should conduct thorough Freedom-to-Operate (FTO) analyses encompassing not just composition patents but method-of-treatment and formulation claims, which often carry the longest effective protection periods.

❓ FAQ

What patents were involved in Salix Pharmaceuticals v. Saba Ilac?

Twelve U.S. patents were asserted, including U.S. Patent Nos. 7,928,115; 8,193,196; 8,309,569; 8,642,573; 8,829,017; 8,946,252; 8,969,398; 10,456,384; 10,765,667; 11,564,912; and 11,779,571, covering rifaximin compositions, formulations, and treatment methods.

Why was the 30-month FDA stay terminated?

As part of the settlement, both parties agreed to terminate the automatic 30-month stay triggered under 21 U.S.C. § 355(j)(5)(B)(iii), allowing Saba Ilac’s ANDA to proceed toward FDA approval under negotiated license terms.

How does this case affect rifaximin patent litigation strategy?

It reinforces that broad pharmaceutical patent portfolios create strong settlement leverage, while generic challengers retaining Paragraph IV certifications can achieve favorable negotiated outcomes without full-scale patent adjudication.